文献速递临床试验与 GCP

口服烟酰胺单核苷酸(NMN)治疗慢性失眠:多中心、随机、双盲、安慰剂对照试验方案

Oral nicotinamide mononucleotide (NMN) to treat chronic insomnia: protocol for the multicenter, randomized, double-blinded, placebo-controlled trial.
PubMed 文献 · Trials · 2023-05-18

本研究为多中心、患者评估者盲法、随机对照试验,计划纳入400例慢性失眠患者,按1:1分配至口服NMN 320 mg/日组或安慰剂组,疗程60天。主要结局为匹兹堡睡眠质量指数(PSQI)评分,次要结局包括失眠严重程度指数(ISI)、Epworth嗜睡量表(ESS)、总睡眠时间(TST)、睡眠效率(SE)、睡眠潜伏期及REM睡眠潜伏期。研究旨在验证NMN改善慢性失眠患者睡眠质量的疗效。

要点

  • 多中心随机双盲安慰剂对照试验,计划纳入400例慢性失眠患者,1:1分组。
  • 干预为口服NMN 320 mg/日,对照为口服安慰剂,疗程60天。
  • 主要结局为PSQI评分,次要结局包括ISI、ESS、TST、SE及睡眠潜伏期等。

核心结论

  • 本研究将为NMN改善慢性失眠患者睡眠质量提供更多证据;若被证实有效,NMN补充剂未来可作为慢性失眠的新治疗方法。

研究设计与样本

  • 多中心、患者评估者盲法、随机对照试验,两平行组,计划纳入400例慢性失眠患者,按1:1分配至口服NMN 320 mg/日组或口服安慰剂组,疗程60天,评估时间点为基线和随访。

关键数值与推荐

  • 主要结局为匹兹堡睡眠质量指数(PSQI)评分。
  • 次要结局为失眠严重程度指数(ISI)评分、Epworth嗜睡量表(ESS)评分、总睡眠时间(TST)、睡眠效率(SE)、睡眠潜伏期及REM睡眠潜伏期。
  • 干预组口服NMN 320 mg/日,对照组口服安慰剂,疗程60天。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The treatment of insomnia, which is the most common sleep disorder, includes drug and behavioral treatment, but each treatment measure has its limitations. So new treatment method needs to be taken to improve the treatment effect. MN supplementation is a potential promising new method for the treatment of insomnia, resulting in a rising need for methodological research towards verifying its efficacy. METHODS/DESIGN: We describe a proposal for a multicenter, patient-assessor-blinded, randomized controlled trial with two parallel arms. A total of 400 chronic insomnia patients will be allocated 1:1 to the intervention group (treatment with oral NMN 320 mg/day) or control group (treatment with oral placebo). All subjects are clinical chronic insomnia patients who meet all inclusion criteria. All subjects are treated by taking NMN or placebo. The primary outcome is the score on the Pittsburgh Sleep Quality Index (PSQI). Secondary outcomes are the score on the Insomnia Severity Index (ISI) and Epworth Sleeping Scale (ESS), the total sleep time (TST), sleep efficiency (SE), sleep latency, and REM sleep latency to assess sleep quality changes. Subjects are assessed at two time points: baseline and follow-up. The duration of the clinical trial is 60 days. DISCUSSION: This study will provide more evidence on the effects of NMN on improving sleep quality among patients with chronic insomnia. If proven effective, NMN supplement can be used as a new treatment for chronic insomnia in the future. TRIAL REGISTRATION: Chinese Clinical Trial Registry (chictr.org.cn) ChiCTR2200058001. Registered on 26 March 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gao X, Li J, Xu S, et al. Oral nicotinamide mononucleotide (NMN) to treat chronic insomnia: protocol for the multicenter, randomized, double-blinded, placebo-controlled trial. Trials. 2023. PMID: 37202819. doi:10.1186/s13063-023-07351-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。